XTrend
MenuXTrend

Stock Charts

Charts can help you clearly see the market trend.

LLY

Eli Lilly and Company

Bid713.37
Ask713.78
Change-1.54
% Chg -0.22%
High719.03
Low708.99

Past performance is not an indication of future results.

About

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Industry

Pharmaceuticals

Stock Exchange

NYSE

Listing Date

01-04-1973

Trading Specifications
Minimum Price Fluctuation
--
Spreads as low as
--
Average Spreads
--
Minimum Lot Size
--
Commission
--
Trading Hours(GMT+2)
--
Maximum Trading Volume (lots)
--
News
Eli Lilly & Co. gives presentation highlights for 2025 ASCO
Lilly announces details of presentations at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Cigna takes different approach with GLP-1s, more favorable for Eli Lilly
Morgan Stanley maintains Eli Lilly stock Overweight rating
Sanofi to acquire Vigil Neuroscience in Alzheimer’s drug play
Australia approves Kisunla for early Alzheimer’s treatment
Lilly receives marketing authorization in Australia for the treatment of early symptomatic Alzheimer’s disease
Eli Lilly at BofA Conference: Strategic Insights on Growth and Challenges
Bernstein reiterates Eli Lilly outperform with $1,100 target
Eli Lilly stock holds $1,100 target, Bernstein positive on EO impact
XTrend

AFA REGIONAL SPONSOR

XTrendEnglish
XTrend
XTrend
XTrend
XTrend
XTrend